Browsing by Author Lang, Istvan

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 16 of 16
Issue DateTitleAuthor(s)Citation
2016Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT TrialsCoates, Alan; Colleoni, Marco; Fleming, Gini; Francis, Prudence; Gelber, Richard; Goldhirsch, A; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Pinotti, Graziella; Price, Karen N; Regan, Meredith; Tondini, Carlo; Viale, Giuseppe; Walley, Barbara; School of Public Health: Public HealthAbsolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, Human epidermal growth factor receptor 2-Negative early breast cancer: TEXT and SOFT Trials, Journal of Clinical Oncology, vol.34, 19, 2016,pp 2221-2230
2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancerCoates, Alan; Burstein, Harold J.; Colleoni, Marco; et al, Various; Fleming, G. F.; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Perez, E. A.; Regan, Meredith M.; Tondini, Carlo; Walley, B; School of Public Health: Public HealthAdjuvant exemestane with ovarian suppression in premenopausal breast cancer, New England Journal of Medicine, vol.371, 2, 2014,pp 107-118
2015Adjuvant ovarian suppression in premenopausal breast cancerCoates, Alan; Bellet, Meritxell; Bonnefoi, Herve; Buchholz, Stefan; Burstein, Harold; Ciruelos, Eva; Climent, Miguel; Coleman, Richard; Colleoni, Marco; Da Prada, Gian; Davidson, Nancy; Fleming, Gini; Francis, Prudence; Gelber, Richard D. (Prof); Geyer, Charles; Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Ingle, J.; Kerbrat, Pierre; Lang, Istvan; Maibach, Rudolph; Martino, Silvana; Price, K. N; Rabaglio-Poretti, Manuela; Regan, Meredith; Ruepp, Barbara; Viale, Giuseppe; Walley, Barbara; Winer, EP; School of Public Health: Public HealthAdjuvant ovarian suppression in premenopausal breast cancer, The New England Journal of Medicine, vol.372, 5, 2015,pp 436-446
2013Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trialCoates, Alan; Crivellari, Diana; Dellapasqua, S; et al, Various; Gianni, Lorenzo; Gray, Kathryn P; Lang, Istvan; Pinotti, Graziella; Price, Karen N; Puglisi, Fabio; Ribi, Karin; Spazzapan, Simon; School of Public Health: Public HealthAdjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial, The Breast, vol.22, 2, 2013,pp 130-137
2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 studyCoates, Alan; Chirgwin, Jacquie H; Colleoni, Marco; Forbes, John F.; Gelber, Richard D. (Prof); Giobbie-Hurder, Anita; Goldhirsch, Aron (Prof); Lang, Istvan; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Pienkowski, Tadeusz; Price, Karen N.; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, Beat; Wardley, Andrew; School of Public Health: Public HealthAnalyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study, Journal of Clinical Oncology, vol.29, 9, 2011,pp 1117-1124
2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-upCoates, Alan; Ejlertsen, Bent; Forbes, John F.; Gelber, Richard; Giobbie-Hurder, Anita; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Neven, Patrick; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, B.; Wardley, Andrew; School of Public Health: Public HealthAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncology, vol.12, 12, 2011,pp 1101-1108
2014Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trialCoates, Alan; Aebi, Stefan; Anderson, Stuart J; Canada, Jose; et al, Various; Gelber, S.; Lang, Istvan; Martin, Miguel; Nortier, Johan; Paterson, Alexander; Rimawi, Mothaffar F; Robidoux, Andre; School of Public Health: Public HealthChemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial, Lancet Oncology, vol.15, 2, 2014,pp 156-163
2017Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 studyCoates, Alan; Ahern, T; Borgquist, Signe; Colleoni, Marco; Debled, Marc; Ejlertsen, Bent; et al, Various; Garber, Judy; Giobbie-Hurder, Anita; Lang, Istvan; von Moos, Roger; NH&MRC Clinical Trials CentreCholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study, Journal of Clinical Oncology, vol.35, 11, 2017,pp 1179-1188
2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFTCoates, Alan; Abdi, Ehtesham; Colleoni, Marco; Fleming, G. F.; Francis, P A; Gelber, Richard; Goldhirsch, A; Gomez, Henry; Lang, Istvan; Pagani, Olivia; Parmar, Vani; Pinotti, Graziella; Regan, Meredith M.; Ruhstaller, Thomas; Salim, Muhammad; Spazzapan, Simon; Tondini, Carlo; Walley, B. A.; NH&MRC Clinical Trials CentreConcurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT, Annals of Oncology, vol.28, 9, 2017,pp 2225-2232
2014Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseBoyle, Frances; Barrios, Carlos; De Azambuja, Evandro; Di Cosimo, Serena; et al, Various; Holmes, Andrew P; Holmes, Eileen; Jackisch, Christian; Lang, Istvan; Perez, E. A.; Piccart-Gebhart, Martine; Smith, Ian (Prof); Swaby, Ramona F; Untch, Michael; Xu, Binghe; Northern Clinical School: MedicineLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response, The Lancet Oncology, vol.15, 10, 2014,pp 1137-1146
2008Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; Chirgwin, Jacquie H; Colleoni, Marco; Crivellari, Diana; Del Mastro, Lucia; Forbes, John F.; Gelber, Richard D. (Prof); Gladieff, Laurence; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Rabaglio, Manuela; Smith, Ian (Prof); Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthLetrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, 12, 2008,pp 1972-1979
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2017Population Pharmacokinetics of Liposomal Irinotecan in Patients With CancerWong, Ka (Mark); Adiwijaya, B. S.; Chen, J. S.; Csoszi, Tibor; Cubillo, A.; et al, Various; Kim, J.; Kim, J. S.; Lang, Istvan; Park, J. O.; Rau, Kunming; Westmead Clinical School: MedicinePopulation Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer, Clinical Pharmacology & Therapeutics, vol.102, 6, 2017,pp 997-1005
2014Symptoms of endocrine treatment and outcome in the BIG 1-98 studyCoates, Alan; Bonnefoi, Herve; Cole, B F; Ejlertsen, Bent; et al, Various; Forbes, John F.; Giobbie-Hurder, Anita; Huober, J; Lang, Istvan; Neven, Patrick; Rabaglio, Manuela; Wu, Junru; School of Public Health: Public HealthSymptoms of endocrine treatment and outcome in the BIG 1-98 study, Breast Cancer Research and Treatment, vol.143, 1, 2014,pp 159-169
2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Coates, Alan; Colleoni, Marco; Dell'Orto, Patrizia; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, A.; Gusterson,, B; Lang, Istvan; MacGrogan, G; Maiorano, Eugenio; Mastropasqua, M; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Price, Karen; Rasmussen, B; Regan, Meredith M.; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial., Annals of Oncology, vol.22, 10, 2011,pp 2201-7